HDAC inhibitors: modulating leukocyte differentiation, survival, proliferation and inflammation
MJ Sweet, MR Shakespear, NA Kamal… - Immunology and cell …, 2012 - Wiley Online Library
Therapeutic effects of histone deacetylase (HDAC) inhibitors in cancer models were first
linked to their ability to cause growth arrest and apoptosis of tumor cells. It is now clear that …
linked to their ability to cause growth arrest and apoptosis of tumor cells. It is now clear that …
Histone deacetylase inhibitors and rational combination therapies
S Grant, Y Dai - Advances in cancer research, 2012 - Elsevier
Histone deacetylase inhibitors (HDACIs) are epigenetically acting agents that modify
chromatin structure and by extension, gene expression. However, they may influence the …
chromatin structure and by extension, gene expression. However, they may influence the …
Elucidating the mechanism of action of domatinostat (4SC-202) in cutaneous T cell lymphoma cells
M Wobser, A Weber, A Glunz, S Tauch, K Seitz… - Journal of Hematology & …, 2019 - Springer
Background Targeting epigenetic modifiers is effective in cutaneous T cell lymphoma
(CTCL). However, there is a need for further improvement of this therapeutic approach …
(CTCL). However, there is a need for further improvement of this therapeutic approach …
The anti‐mitotic agents PTC‐028 and PTC596 display potent activity in pre‐clinical models of multiple myeloma but challenge the role of BMI‐1 as an essential …
A Bolomsky, J Muller, K Stangelberger… - British journal of …, 2020 - Wiley Online Library
Future progress in the treatment of multiple myeloma (MM) requires both the
characterisation of key drivers of the disease and novel, innovative approaches to tackle …
characterisation of key drivers of the disease and novel, innovative approaches to tackle …
Belinostat and vincristine demonstrate mutually synergistic cytotoxicity associated with mitotic arrest and inhibition of polyploidy in a preclinical model of aggressive …
Diffuse Large B-cell lymphoma (DLBCL) is an aggressive malignancy that has a 60 percent
5-year survival rate, highlighting a need for new therapeutic approaches. Histone …
5-year survival rate, highlighting a need for new therapeutic approaches. Histone …
A model of sensitivity and resistance to histone deacetylase inhibitors in diffuse large B cell lymphoma: Role of cyclin-dependent kinase inhibitors
AA Tula-Sanchez, AP Havas, PJ Alonge… - Cancer biology & …, 2013 - Taylor & Francis
Diffuse large B cell lymphoma (DLBCL) is an aggressive form of non-Hodgkin lymphoma.
While the initial treatment strategy is highly effective, relapse occurs in 40% of cases …
While the initial treatment strategy is highly effective, relapse occurs in 40% of cases …
In Vitro and In Vivo Interactions between the HDAC6 Inhibitor Ricolinostat (ACY1215) and the Irreversible Proteasome Inhibitor Carfilzomib in Non-Hodgkin …
G Dasmahapatra, H Patel, J Friedberg… - Molecular cancer …, 2014 - AACR
Interactions between the HDAC6 inhibitor ricolinostat (ACY1215) and the irreversible
proteasome inhibitor carfilzomib were examined in non-Hodgkin lymphoma (NHL) models …
proteasome inhibitor carfilzomib were examined in non-Hodgkin lymphoma (NHL) models …
The multi zinc-finger protein Trps1 acts as a regulator of histone deacetylation during mitosis
M Wuelling, M Pasdziernik, CN Moll, AM Thiesen… - Cell Cycle, 2013 - Taylor & Francis
TRPS1, the gene mutated in human" Tricho-Rhino-Phalangeal syndrome," encodes a multi
zinc-finger nuclear regulator of chondrocyte proliferation and differentiation. Here, we have …
zinc-finger nuclear regulator of chondrocyte proliferation and differentiation. Here, we have …
[PDF][PDF] Charakterisierung der Klasse I Histondeacetylasen als Zielmoleküle für die Therapie des Urothelkarzinoms
M Pinkerneil - 2018 - d-nb.info
Klasse I HDACs sind in vielen Krebsentitäten an der Entwicklung und Progression von
Tumoren beteiligt. Ihre Inhibition führt oft zu starken antineoplastischen Effekten; es ist …
Tumoren beteiligt. Ihre Inhibition führt oft zu starken antineoplastischen Effekten; es ist …
Defining mechanisms of sensitivity and resistance to histone deacetylase inhibitors to develop effective therapeutic strategies for the treatment of aggressive diffuse …
AP Havas - 2016 - search.proquest.com
Diffuse large B-cell lymphoma (DLBCL) is the most common form of non-Hodgkin lymphoma
(NHL). The current standard of care is the combination of rituximab with cyclophosphamide …
(NHL). The current standard of care is the combination of rituximab with cyclophosphamide …